ARS Pharmaceuticals, Inc. SPRY Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.68M-19.2% | $28.09M-13.6% | $32.5M+107% | $15.72M+97.1% | $7.97M-90.8% | ||
| $4.34M+25.9% | $3.44M+25.2% | $2.75M-31.8% | $4.04M+36.7% | $2.95M-2.5% | ||
| $72.2M+20.4% | $59.96M-19.8% | $74.75M+37.6% | $54.31M+32.1% | $41.1M+15.8% | ||
| $82.83M+19.1% | $69.55M-18.8% | $85.69M+35.3% | $63.33M+40.3% | $45.15M+14.6% | ||
| -$60.15M-45.1% | -$41.47M+22.0% | -$53.19M-11.7% | -$47.61M-28.1% | -$37.18M— | ||
| -265.2%-118pp | -147.6%+16.0pp | -163.7%+139pp | -302.9%+163pp | -466.3%— | ||
| -$473K-875% | $61K-97.0% | $2.04M-25.3% | $2.73M-15.6% | $3.24M+7.0% | ||
| —— | -$42.84M0.0% | -$42.84M0.0% | -$42.84M0.0% | -$42.84M-2,168% | ||
| —— | -$20K0.0% | -$20K0.0% | -$20K0.0% | -$20K-128% | ||
| -$60.62M-46.7% | -$41.32M+19.2% | -$51.15M-14.0% | -$44.88M-32.2% | -$33.94M-168% | ||
| -267.3%-120pp | -147.1%+10.3pp | -157.4%+128pp | -285.6%+140pp | -425.7%-483pp | ||
| -$0.61-45.2% | -$0.42+19.2% | -$0.52-13.0% | -$0.46-31.4% | -$0.35-169% | ||
| -$59.75M-45.6% | -$41.05M+22.3% | -$52.8M-11.5% | -$47.34M-28.3% | -$36.9M-1,857% | ||
| -263.4%-117pp | -146.1%+16.3pp | -162.5%+139pp | -301.2%+162pp | -462.8%-465pp | ||
| -$60.15M-45.1% | -$41.47M+22.0% | -$53.19M-11.7% | -$47.61M-28.1% | -$37.18M-1,895% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s revenue?
- ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.
- Is ARS Pharmaceuticals, Inc. profitable?
- ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.
- What is ARS Pharmaceuticals, Inc.'s earnings per share?
- ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.
- Where does ARS Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
